eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study

Juan-Alfonso Soler, Mercé Güell, Meritxell Bricullé, Antoni Gavarró, Imma Roig, Jordi Sanchez, Javier P. Gisbert, Pilar García, Albert Villoria, Xavier Calvet

► To cite this version:

Juan-Alfonso Soler, Mercé Güell, Meritxell Bricullé, Antoni Gavarró, Imma Roig, et al.. eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study. *Annals of Hematology*, 2009, 88 (8), pp.769-773. 10.1007/s00277-008-0684-4 . hal-00535021

HAL Id: hal-00535021

<https://hal.science/hal-00535021>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

***H. pylori* eradication does not reduce paraprotein levels in monoclonal gammopathy of unknown significance (MGUS): a prospective cohort study**

Juan-Alfonso Soler · Mercé Güell · Meritxell Bricullé ·
Antoni Gavarró · Imma Roig · Jordi Sanchez ·
Javier P. Gisbert · Pilar García · Albert Villoria ·
Xavier Calvet

Received: 4 July 2008 / Accepted: 18 December 2008 / Published online: 22 January 2009
© Springer-Verlag 2009

Abstract Monoclonal gammopathy of unknown significance (MGUS) is a chronic haematological alteration that carries a 1% risk per year of malignant evolution. The origin of this disturbance remains unknown. Previous reports have suggested that a subgroup of patients presenting MGUS might cure after *Helicobacter pylori* eradication. This study evaluates the effect of *H. pylori* eradication in a cohort of 30 patients with MGUS. A 7-day clarithromycin-based triple treatment was prescribed to patients with MGUS infected with *H. pylori*. Quantification of the monoclonal component was performed at inclusion and at least 12 months after treatment. The monoclonal component persisted unchanged in all patients who cured the *H. pylori* infection.

Keywords Monoclonal gammopathy of unknown significance · *Helicobacter pylori* · Eradication therapy

J.-A. Soler (✉) · I. Roig
Servei d'Hematologia, Hospital de Sabadell, Institut Universitari
Parc Taulí, Universitat Autònoma de Barcelona,
Parc Taulí, s/n, 08208 Sabadell,
Barcelona, Spain
e-mail: jsoler@tauli.cat

J. Sanchez · P. García · A. Villoria · X. Calvet
Digestive Diseases Unit, Hospital de Sabadell,
Institut Universitari Parc Taulí, Departament de Medicina,
Universitat Autònoma de Barcelona,
Barcelona, Spain

M. Bricullé
Nefrology Department, Hospital de Sabadell,
Institut Universitari Parc Taulí, Departament de Medicina,
Universitat Autònoma de Barcelona,
Barcelona, Spain

Introduction

Monoclonal gammopathy of unknown significance (MGUS) is a chronic haematological disturbance mainly affecting advanced age individuals. Although it is usually asymptomatic, MGUS carries a 1% risk per year of malignant disease, mostly multiple myeloma [1]. *Helicobacter pylori* infection is a well-known cause of gastric and duodenal disease, mainly peptic ulcer and gastric adenocarcinoma. *H. pylori* has been associated with some haematological disorders and, specifically, with idiopathic thrombocytopenic purpura [2, 3]. Thus, there is growing evidence that near 30% of patients with this disease improve after *H. pylori* eradication. *H. pylori* infection is also the main etiological factor in low-grade gastric mucosa-associated lymphatic tissue (MALT) lymphoma. It has been shown that *H. pylori* infection produces a

M. Güell
Servei de Cirurgia, Hospital de Manresa, Althaia,
Manresa, Barcelona, Spain

A. Gavarró
Laboratori d'Anàlisis Clínics UDIAT-CD Corporació Parc Taulí,
Sabadell, Barcelona, Spain

J. Sanchez · J. P. Gisbert · P. García · A. Villoria · X. Calvet
CIBEREHD, Instituto de Salud Carlos III,
Madrid, Spain

J. P. Gisbert
Hospital de la Princesa,
Madrid, Spain

monoclonal expansion of B cells, finally leading to the appearance of the lymphoma [4]. Furthermore, cure of the infection leads to a long-term remission in most cases of localised disease [5, 6]. Being also a monoclonal B cell proliferation, it seemed reasonable that chronic antigenic stimulation from the life-long colonisation of gastric lumen by *H. pylori* could be the cause in some cases of MGUS. In fact, monoclonal gammopathy associated to a Russell bodies gastritis have been described [7, 8], and a few cases of progression from MGUS to gastric MALT lymphoma have been also reported [9].

A recent report has suggested that a proportion of MGUS patients could respond to *H. pylori* eradication. Thus, Malik et al. [10] found a complete response—with disappearance of the monoclonal component from the bloodstream—in 11 of 39 (28%) patients with the disease. These findings, however, have been subsequently challenged. Thus, Rajkumar et al. [11] did not find any evidence of response in a retrospective series of MGUS patients at Mayo Clinic. Later, other authors had shown that eradication of *H. pylori* did not change MGUS evolution in a case report [8] nor in a series of eight patients with associated MGUS and chronic idiopathic neutropenia [12]. Finally, very recently, Veneri et al. [13] treated 16 MGUS patients infected with *H. pylori*. Paraprotein levels remained unchanged in the 15 patients who cured the infection. According to these contradictory data, the evidence on the relationship between MGUS and *H. pylori* infection remains still controversial. The objective of the study was therefore to evaluate if eradication of *H. pylori* eradication could lead to resolution of monoclonal component in patients with MGUS.

Materials and methods

Patients with MGUS diagnosed according to standard Kyle criteria [14] at least 6 months before were included. Patients were given information on the nature and risks of *H. pylori* infection and of the controversial evidence on the possibility of response of their disease to *H. pylori* eradication. Testing for the infection and treatment was proposed. The study was approved by the Ethical Committee of the Hospital de Sabadell. In patients who accepted to participate, written informed consent was obtained.

Determination of *H. pylori* status and treatment

Urea breath test (UBT) was performed according to the Standard European protocol [15]. Patients with a positive UBT received 7-day standard triple therapy including a proton pump inhibitor at standard doses, amoxicillin 1 g and clarithromycin 500 mg all twice a day. Eradication was

evaluated by UBT at least 2 months after eradication. Rescue treatment for patients who failed first-line therapy consisted of 10 days of quadruple therapy with a proton pump inhibitor twice a day, plus tetracycline 500 mg, metronidazole 500 mg and bismuth subcitrate 120 mg all three times a day. Again, an UBT was performed at least 2 months after the end of the treatment.

Determination of the monoclonal component

Cell blood count (CBC), total protein determination and the quantification of monoclonal component were performed at inclusion and at every 6 months.

Statistical analysis

Data are given as mean $\pm$ SE. Proportions are given along with their 95% confidence interval. The Wilcoxon test for paired samples was performed to compare the monoclonal component at inclusion and at the end of follow-up. Sample size calculation: According to previous data, we expected a 25% response rate in patients cured of *H. pylori* infection. To estimate the percentage of responses $\pm 20\%$ with a 95% confidence interval, a sample of 20 cured patients was required. Assuming an 80% cure rate of infection and a 20% of losses to follow-up, a sample of 28 treated patients was needed.

Results

Between January 2002 and December 2005, 99 patients were evaluated for inclusion. Fifty-six were males. Mean age was 70.3 ± 12 years. Gammopathy was IgA in 17 cases, IgG in 68 and IgM in 13. The light chain type was kappa in 56 cases and lambda in the remaining 42. One patient presented a combined IgG and IgA gammopathy with combined kappa and lambda components. Median time since the diagnosis was 40 months ranging from 6 to 87 months. Forty-four patients did not agree to participate in the study. Of the remaining, nine were *H. pylori*-negative (group 1). Sixteen positive patients did not accept eradication treatment. Finally, 30 received eradication therapy with a proton pump inhibitor at standard doses, amoxicillin 1 g and clarithromycin 500 mg all twice a day for a week, 11 being cured (37%). Three patients who did not cure the infection after first-line treatment accepted a second treatment, and two of them were cured. Thus, after two treatments, 13 patients (group 2) were cured and 33 (16 not treated and 17 treatment failures) remained infected (group 3). A flow diagram of the study is shown in Fig. 1. Characteristics of the patients included in each group are depicted in Table 1.

Fig. 1 Flow chart of the patients included in the study

Median follow-up was 19.6 months. None of the patients progressed to multiple myeloma during follow-up. Also, CBC and total protein neither show significant changes in the whole group nor in the different subgroups in the study. Neither monoclonal gradient nor light chain concentrations decreased in any of the determinations performed after *H. pylori* eradication. On the contrary, mean monoclonal

Table 1 Characteristics of patients

	<i>H. pylori</i> - negative (n=9)	Eradicated (n=13)	<i>H. pylori</i> infection (n=33)
Male	3	9	20
Age (mean ± SD)	69.3±2	64.2±4	69.2±4
IgA/IgG/IgM	3:5:1	2:10:1	3:27:4 ^a
Light chain (κ/λ)	3:6	6:7	20:14 ^a
Time since the diagnosis (months)	38.5±10	40±7	32.5±5
Follow-up (months)	21.6±2	26.7±2	23.7±1
Monoclonal component (g/l)	15.7±1	15.6±9	15.9±1

^a One patient had a mixed IgA/IgG monoclonal component, with light chains mixed (κ/λ)

Fig. 2 Monoclonal component values before inclusion and at the end of follow-up in the different groups of patients. Hp- *H. pylori* negative (group 1), Hp+ infected by *H. pylori*. Cured (Group 2) and not cured (group 3)

component of the whole group significantly increased from 15.8 ± 5.3 at the beginning to 18.2 ± 5.3 g/l ($p < 0.001$) at the end of follow-up. Changes in the monoclonal component were: 2.7 ± 0.4 , 1.4 ± 0.3 and 1.9 ± 0.6 in groups 1 to 3, respectively (Fig. 2). In addition, the monoclonal component persisted unchanged or increased in 100% (95%CI, 72–100%) of the 13 patient who cured the *H. pylori* infection (Fig. 3).

Discussion

Contrasting the initial results of Malik et al. [10], the present series strongly suggests that *H. pylori* eradication does not induce MGUS regression. None of the patients in whom eradication treatment was effective normalised the monoclonal component. Nor even an isolated minor decrease was found. By contrast, in patients in whom the infection was eradicated, the monoclonal component slowly increased to the same degree as in patients with persistent infection or in those without *H. pylori* infection. The study findings were very similar to those found by Veneri et al. [13] who did not found a response in any of 15 treated patients in a similar study. Putting these results together, it

Fig. 3 Value of the monoclonal component before eradication and at the end of follow-up in the patients who cured *H. pylori* infection

could be reliably affirmed that at least for the vast majority of MGUS patients, treating *H. pylori* did not lead to a reduction of paraprotein. Monoclonal gammopathy has also been described in a small subgroup of patients with MALT lymphoma [16, 17]. However, even in these cases, paraprotein has been associated with a poor response of the lymphoma to *H. pylori* eradication, thus requiring radiation or chemotherapy. In this setting, paraprotein decreases have been observed in those patients responding treatment. It has been suggested therefore that paraprotein production could be a marker for more aggressive disease [16, 17].

Two aspects of this study merit to be discussed. First, why could the low cure rate of *H. pylori* infection be explained and second how strongly could be affirmed that *H. pylori* eradication treatment is ineffective for curing MGUS with 13 patients cured of the infection.

Regarding the first aspect, patient with MGUS are generally of advanced age and often had associated diseases. Antibiotic treatments for respiratory and urinary tract infections are likely to be frequently prescribed. As previous use of macrolides is one of the best predictors for failure of standard triple therapy [18], this fact could account for at least a part of the failures. In fact, although *H. pylori* resistance to clarithromycin in the elderly was not very frequent some years ago, antibiotic resistances have been steadily increasing in last years, especially in populations receiving frequent antibiotic treatment as children [19]. Additionally, triple therapy seems to be less effective in patients with dyspepsia without ulcer than in those obtained in peptic ulcer patients. It has been hypothesised that a lower degree of inflammation in non-ulcer dyspepsia was associated with a decreased permeability to antibiotics or to a lower degree of immune response against the bacteria [20].

The second point is how reliable are the negative results of our study. Despite the small number of patients that cured the infection at the end of the study, zero cured patients out of 13 treated has a strong negative predictive value. It could be calculated that with a degree of confidence of 90%, the maximum possible MGUS cure rate attributable to eradication is lower than 13%. In addition, as stated, a very similar study of Veneri et al. [13] also did not found any response in 15 additional patients after *H. pylori* eradication. Taking into account that no patient showed a normalisation or even a decrease in paraprotein levels in the two studies, the residual probability that eradicating *H. pylori* had a clinically significant effect in MGUS is extremely low.

In conclusion, our study adds strength to the previous evidence against the hypothesis that *H. pylori* eradication might have a beneficial effect on MGUS evolution. In addition, it shows that at least in some selected populations, standard triple therapy achieves very low eradication rates.

Acknowledgements This study has been supported by grants from the Instituto de Salud Carlos III (C03/02 and PI 05/1157 and CIBEREHD) from the Agència de Gestió d'Ajuts Universitaris i de Recerca de la Generalitat de Catalunya (2004ACOM 00041) and from the Societat Catalana de Digestologia.

References

- Blade J (2006) Clinical practice. Monoclonal gammopathy of undetermined significance. *N Engl J Med* 355:2765–2770, doi:10.1056/NEJMc052790
- Malfetheriner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakili N, Kuipers EJ (2007) Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 56:772–781, doi:10.1136/gut.2006.101634
- Emilia G, Luppi M, Zucchini P, Morselli M, Potenza L, Forghieri F, Volzone F, Jovic G, Leonardi G, Donelli A, Torelli G (2007) *Helicobacter pylori* infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. *Blood* 110:3833–3841, doi:10.1182/blood-2006-12-063222
- Nakamura S, Aoyagi K, Furuse M, Suekane H, Matsumoto T, Yao T, Sakai Y, Fuchigami T, Yamamoto I, Tsuneyoshi M, Fujishima M (1998) B-cell monoclonality precedes the development of gastric MALT lymphoma in *Helicobacter pylori*-associated chronic gastritis. *Am J Pathol* 152:1271–1279
- Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su JJ, Whang-Peng J, Cheng AL (2005) Long-term results of anti-*Helicobacter pylori* therapy in early-stage gastric high-grade transformed MALT lymphoma. *J Natl Cancer Inst* 97:1345–1353
- Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdorffer E, Stolte M, Neubauer A (2005) Long-term follow-up of gastric MALT lymphoma after *Helicobacter pylori* eradication. *J Clin Oncol* 23:8018–8024, doi:10.1200/JCO.2005.02.3903
- Pizzolitto S, Camilot D, DeMaglio G, Falconieri G (2007) Russell body gastritis: expanding the spectrum of *Helicobacter pylori*-related diseases? *Pathol Res Pract* 203:457–460, doi:10.1016/j.prp.2007.01.009
- Wolkersdorfer GW, Haase M, Morgner A, Baretton G, Miehlke S (2006) Monoclonal gammopathy of undetermined significance and Russell body formation in *Helicobacter pylori* gastritis. *Helicobacter* 11:506–510, doi:10.1111/j.1523-5378.2006.00443.x
- Tursi A, Modeo ME (2002) Monoclonal gammopathy of undetermined significance predisposing to *Helicobacter pylori*-related gastric mucosa-associated lymphoid tissue lymphoma. *J Clin Gastroenterol* 34:147–149, doi:10.1097/00004836-200202000-00009
- Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF (2002) Role of *Helicobacter pylori* infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. *Am J Gastroenterol* 97:1371–1374, doi:10.1111/j.1572-0241.2002.05668.x
- Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Thernau TM (2002) *Helicobacter pylori* infection and monoclonal gammopathy of undetermined significance. *Br J Haematol* 119:706–708, doi:10.1046/j.1365-2141.2002.03912.x
- Papadaki HA, Pontikoglou C, Stavroulaki E, Minadakis G, Eliopoulos DA, Pyrovolaki K, Skordilis P, Eliopoulos GD (2005) High prevalence of *Helicobacter pylori* infection and

- monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia. *Ann Hematol* 84:317–320, doi:[10.1007/s00277-004-0996-y](https://doi.org/10.1007/s00277-004-0996-y)
13. Veneri D, Franchini M, Pizzolo G (2006) Monoclonal gammopathy of undetermined significance and *Helicobacter pylori* infection. *Ann Hematol* 85:807–809, doi:[10.1007/s00277-006-0155-8](https://doi.org/10.1007/s00277-006-0155-8)
 14. Kyle RA (1993) “Benign” monoclonal gammopathy—after 20 to 35 years of follow-up. *Mayo Clin Proc* 68:26–36
 15. Dominguez-Munoz JE, Leodolter A, Sauerbruch T, Malfertheiner P (1997) A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of *Helicobacter pylori* infection. *Gut* 40:459–462
 16. Wohrer S, Streubel B, Bartsch R, Chott A, Raderer M (2004) Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. *Clin Cancer Res* 10:7179–7181, doi:[10.1158/1078-0432.CCR-04-0803](https://doi.org/10.1158/1078-0432.CCR-04-0803)
 17. Wohrer S, Troch M, Streubel B, Hoffmann M, Mullauer L, Chott A, Raderer M (2007) Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. *Ann Oncol* 18:2020–2024, doi:[10.1093/annonc/mdm375](https://doi.org/10.1093/annonc/mdm375)
 18. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, Reasonover AL, Hurlburt DA, Bruce MG, Sacco F, Butler JC (2003) The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for *Helicobacter pylori* infections. *Ann Intern Med* 139:463–469
 19. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG (2006) *Helicobacter pylori* and antimicrobial resistance: molecular mechanisms and clinical implications. *Lancet Infect Dis* 6:699–709, doi:[10.1016/S1473-3099\(06\)70627-2](https://doi.org/10.1016/S1473-3099(06)70627-2)
 20. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP (2005) Seven versus ten days of rabeprazole triple therapy for *Helicobacter pylori* eradication: a multicenter randomized trial. *Am J Gastroenterol* 100:1696–1701, doi:[10.1111/j.1572-0241.2005.50019.x](https://doi.org/10.1111/j.1572-0241.2005.50019.x)